Status:

UNKNOWN

NT-proBNP Measurements to Rule-out Heart Failure Among Patients With Atrial Fibrillation: A Prospective Clinical Study

Lead Sponsor:

University of Aarhus

Collaborating Sponsors:

Randers Regional Hospital

Conditions:

Atrial Fibrillation

Heart Failure

Eligibility:

All Genders

Brief Summary

This study aims to investigate N-terminal pro brain natriuretic peptide (NT-proBNP) as a biomarker to rule out heart failure in patients with atrial fibrillation. Atrial fibrillation and heart failure...

Detailed Description

Background and hypothesis: Atrial fibrillation is the most common cardiac arrhythmia with a prevalence of approximately 2% in the general population and even higher among elderlies. Atrial fibrillati...

Eligibility Criteria

Inclusion

  • Admission to hospital with atrial fibrillation
  • On-going atrial fibrillation documented on an ECG

Exclusion

  • \<18 years
  • Other arrhythmias than atrial fibrillation
  • Hemodynamically unstable
  • Terminal renal failure (in dialysis)
  • Pregnancy

Key Trial Info

Start Date :

November 11 2019

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

March 1 2021

Estimated Enrollment :

403 Patients enrolled

Trial Details

Trial ID

NCT04125966

Start Date

November 11 2019

End Date

March 1 2021

Last Update

October 12 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Randers Regional Hospital

Randers, Denmark, 8930

NT-proBNP Measurements to Rule-out Heart Failure Among Patients With Atrial Fibrillation: A Prospective Clinical Study | DecenTrialz